US Pharma MarketingBoehringer furthers inflammatory expansion with €407M biobucks bet on Immunitas asset
Boehringer furthers inflammatory expansion with €407M biobucks bet on Immunitas asset is a pharma and life sciences industry update from FierceBiotech. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.
Boehringer Ingelheim has put up 407.5 million euros in biobucks to secure global rights to a first‑in‑class antibody Immunitas Therapeutics is developing for chronic inflammatory and autoimmune diseases.
Source: FierceBiotech